Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 160-163

  Niikura, Masahiro ^a   Bance, Nicole ^a   Mohan, Sankar ^a   Mario Pinto, B ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Group 1 neuraminidase; Influenza A virus; Neuraminidase inhibitors; Oseltamiver derivatives; Replication inhibition; The 150 cavity

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; GUANIDINE DERIVATIVE; OSELTAMIVIR; TRIAZOLE DERIVATIVE; VIRUS SIALIDASE; ZANAMIVIR;

ARTICLE; CONTROLLED STUDY; HYDROGEN BOND; IC 50; IN VITRO STUDY; INFLUENZA A; INFLUENZA VIRUS A; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; KINETICS; MOLECULAR STRUCTURE; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS;

EID: 79953856447     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.03.180     Document Type: Article

References (17)

1. Brown E.G., Liu H., Kit L.C., Baird S., Nesrallah M. Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes. Proc. Natl. Acad. Sci. USA 2001, 98:6883-6888.
2. Calligari P.A., Kneller G.R., Giansanti A., Ascenzi P., Porrello A., Bocedi A. Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: a comparative structural analysis by the ScrewFit algorithm. Biophys. Chem. 2009, 141:117-123.
3. Crusat M., de Jong M.D. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir. Ther. 2007, 12:593-602.
4. Dapat C., Suzuki Y., Saito R., Kyaw Y., Myint Y.Y., Lin N., Oo H.N., Oo K.Y., Win N., Naito M., Hasegawa G., Dapat I.C., Zaraket H., Baranovich T., Nishikawa M., Saito T., Suzuki H. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg. Infect. Dis. 2010, 16:493-496.
5. Fouchier R.A.M., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., Osterhaus A.D.M.E. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 2005, 79:2814-2822.
6. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45:2723-2732.
7. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 2009, 48(Suppl. 1):S3-13.
8. Hurt A.C., Holien J.K., Parker M., Kelso A., Ian G., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
9. Memoli M.J., Morens D.M., Taubenberger J.K. Pandemic and seasonal influenza: therapeutic challenges. Drug Discov. Today. 2008, 13:590-595.
10. Mohan S., McAtamney S., Haselhorst T., von Itzstein M., Pinto B.M. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J. Med. Chem 2010, 53:7377-7391.
11. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., Xu X., Shaw M.W., Kilmov A.I., Gubareva L.V. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A (H1N1) viruses. Antiviral. Res. 2010, 85:381-388.
12. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
13. Sidwell R.W., Smee D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral. Res. 2000, 48:1-16.
14. The Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. New Engl. J. Med. 362, 1708-1719. Erratum in: New Engl. J. Med. 2010. 362, 2039.
15. Ujike M., Shimabukuro K., Mochizuki K., Obuchi M., Kageyama T., Shirakura M., Kishida N., Yamashita K., Horikawa H., Kato Y., Fujita N., Tashiro M., Odagiri T., Working Group for Influenza Virus Surveillance in Japan1 Oseltamivir-Resistant Influenza Viruses A (H1N1) during 2007-2009 Influenza Seasons. Japan. Emerg. Infect. Dis. 2010, 16:926-935.
16. van der Vries E., Stelma F.F., Boucher C.A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. New Engl. J. Med. 2010, 363:1381-1382.
17. Yen H.-L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., Govorkova E.G. Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility Antimicrob. Agents Chemother. 2005, 49:4075-4084.